YAFO Capital

Vol. 32, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 From October 19 to 25, a total of 11 licensing and cooperation agreements were signed worldwide.  In China's biotech industry, two domestic deals were recorded. Lyvgen Biopharma and InventisBio entered into an asset acquisition agreement for three target antibodies, while Haihe Biopharma and 3SBio signed a licensing agreement for the approved oral paclitaxel. On the global stage, 9 licensing and cooperation deals were finalized. The top transaction of the week was a licensing agreement between MacroGenics and Tersera for the approved asset Margetuximab, with a total deal value of $75 million and an upfront payment of $40 million. 10月19-25日，全球医药市场共签署了11项资产授权和合作协议。 中国市场共达成2项国内交易。益方生物收购礼进生物三个目标抗体，三生制药引进海和药物已上市药物紫杉醇口服溶液。 国际市场上，共签署了9项资产授权和合作协议。最大的一笔交易是MacroGenics与Tersera就前者已上市药物margetuximab达成的授权交易，首付款4000万美元，总价值7500万美元。 #BiotechDeals #LicensingAgreements #GlobalPharma #ChinaBiotech https://lnkd.in/gbu5hU6S 

Vol.31, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 Between October 12 and 18, a total of 11 global licensing and cooperation deals were signed. In the China biotech sector, there was one notable out-licensing deal between BaiyuTechnology Pharmaceutical and Novartis for a small molecule anti-tumor drug, with a total deal value of $1.17 billion, including an upfront payment of $70 million. On a global scale, 10 additional licensing and cooperation deals were finalized. The largest deal of the week was the option, cooperation, and licensing agreement between TrianaBiomedicines and Pfizer for preclinical molecular glue degraders, valued at $1.549 billion, including a $49 million upfront payment. #ChinaBiotech #LicensingDeals #PharmaLicensing https://lnkd.in/gzdkX53g

Vol.30, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 In the first two weeks of October, a total of 36 licensing and cooperation deals were signed globally. Within China’s biotech industry, 6 out-licensing deals, 1 in-licensing deal, and 3 domestic deals were finalized. The largest out-licensing deal involved CSPC Pharma and AstraZeneca, with a total deal value of $2.02 billion, including a $100 million upfront payment for the cardiovascular asset YS2302018. The sole in-licensing deal was between Talem Therapeutics and Biotheus for the pre-clinical oncology asset TATX-20. Meanwhile, the leading domestic deal was signed between YZY Biopharma and Chia Tai TianqingPharmaceutical for the Phase III asset M701, valued at $141 million. Globally, 26 licensing and cooperation deals were completed. The top deal was an asset acquisition between Sanofi and Recordati for the approved asset sutimlimab, with a total deal value of $1.1 billion, including an upfront payment of $850 million. 2024年10月的前两周，全球医药市场共签署了36项资产授权和合作协议。中国市场达成10项交易，包括6项出海交易、1项引进交易和3项国内交易。 中国市场最引人注目的出海交易是阿斯利康与石药集团就心血管资产YS2302018达成的授权交易，首付1亿美元，总价值20.2亿美元。唯一的一项引进交易是普米斯就Talem Therapeutics临床前肿瘤资产TATX-20达成的许可交易。最领先的国内交易是正大天晴引进友芝友生物临床三期资产M701，总价值1.41亿美元。 国际市场上，共签署了26项资产授权和合作协议。最大的一笔交易是Recordati收购赛诺菲已上市药物sutimlimab，首付款8.5亿美元，总价值11亿美元。 #BiotechDeals #LicensingAgreements #PharmaPartnerships #OncologyDeals https://lnkd.in/gN4fAjUC

2024 Sep- YAFO Global Biopharma Transactions Report 雅法全球生物医药交易月报 In September, deal-making activity saw an uptick, with 60 transactions worldwide—a 28% increase compared to August, which recorded 47 deals globally. August had a stronger focus on China's biotech sector, representing 24 deals, while September saw 19 deals (9 out-licensing, 4 in-licensing, and 6 domestic). The most notable out-licensing agreement in September was between Regor Therapeutics and Genentech for a portfolio of next-generation CDK Inhibitors with an upfront payment of $850 million, becoming the largest out-licensing transaction in history based on upfront payment. On the in-licensing front, ENCell and Lucy Biotech signed a deal for EN001, valued at approximately $20 million, including a $2 million upfront payment. Domestically, the standout transaction involved Alphamab Oncology and CSPC PHARMA for the oncology asset JSKN-003, with a total deal value of $427 million, including a $55 million upfront payment. Globally, 41 licensing and collaboration agreements were announced in September. The largest of these was a partnership between Orano Med, RadioMedix, and Sanofi for 212Pb-dotamtate, valued at $346 million, with an upfront payment of $108 million. 2024年9月，全球医药市场共签署了60项资产授权和合作协议，同比8月的47项增加了28%。中国市场达成19项交易，包括9项出海交易、4项引进交易和6项国内交易，低于8月份的24项交易。 本月中国市场最引人注目的出海交易是基因泰克收购锐格医药下一代CDK抑制剂，首付8.5亿美元，成为史上最高首付款的出海交易。最值得关注的引进交易是露曦生物从ENCell 公司引进EN001，首付200万美元，总价值约2000万美元。最值得关注的国内交易是石药集团引进康宁杰瑞肿瘤资产JSKN-003，首付款5500万美元，总价值4.27亿美元。 国际市场上，9月份共签署了41项资产授权和合作协议。最大的一笔交易是是赛诺菲与Orano Med和RadioMedix就二期肿瘤资产212Pb-dotamtate达成的授权交易，首付款1.08亿美元，总价值3.46亿美元。 #ChinaBiotech #LicensingDeals #GlobalBiotech https://lnkd.in/gTGQPgzx

GV20 Therapeutics to Speak at ACCESS CHINA Partnering Forum September 24th, 2024 (Shanghai) — We are glad to announce that Dr. Xiaole Shirley Liu, the Co-founder and Chief Executive Officer of GV20 Therapeutics, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. https://lnkd.in/gUQe2ehk

Vol.29, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报 From September 14 to 20, 14 licensing and collaboration deals were signed globally. In the China Biotech Industry, Altamira Therapeutics secured an in-licensing agreement with Nuance Pharma for Bentrio®, expanding its reach across Southeast and East Asia. Additionally, Betta Pharmaceuticals signed a regional distribution agreement with Healthgen Biotechnology for plant-derived OsrHSA, and Huisheng Bio partnered with Huadong Medicine for the exclusive commercialization of Janagliflozin. Globally, 11 licensing and cooperation agreements were finalized that week, with the largest being between Capricor Therapeutics and Nippon Shinyaku for the Phase III asset Deramiocel, valued at $735 million, which includes a $20 million upfront payment. #BiotechDeals #PharmaLicensing #GlobalPharma #Biotechnology https://lnkd.in/g9zdfGGZ

ABION, Inc. to Speak at ACCESS CHINA Partnering Forum September 23rd, 2024 (Shanghai) — We are glad to announce that Hong Seok Choi, Business Development of Abion Inc., will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. https://lnkd.in/gksubZt6

MediSieve to Speak at ACCESS CHINA Partnering Forum September 23rd, 2024 (Shanghai) — We are glad to announce that Dr. George Frodsham, the Founder & Chief Executive Officer of MediSieve, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase from September 24th to 25th, and 27th, 2024. https://lnkd.in/gw5JfFgm

NGB Innovation to Speak at ACCESS CHINA Partnering Forum September 19th, 2024 (Shanghai) — We are glad to announce that Nan Zhang, the Founder & Chief Executive Officer of NGB Innovation, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. https://lnkd.in/gfx8Yaic

Prof. Jinxin Wang's Team to Speak at ACCESS CHINA Partnering Forum September 12th, 2024 (Shanghai) — We are glad to announce that Prof. Jinxin Wang, Professor/Ph.D. Supervisor at China Pharmaceutical University’s Department of Medicinal Chemistry, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. https://lnkd.in/gGRSuCbR